Clinical Trial: SYH2095 for Advanced Malignant Tumors: Phase I Study

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07692776) titled 'SYH2095 for Advanced Malignant Tumors: Phase I Study' on June 29.

Brief Summary: This is an open-label, multicenter Phase 1 first-in-human trial of SYH2095, a selective KAT6A/B inhibitor. The trail contains two segments: Part 1A dose escalation and Part 2A cohort expansion. Part 1A uses the BOIN dose-escalation design, enrolling patients with advanced malignant tumors with no effective standard treatment. Its primary goals are to assess safety and tolerability, define dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), and establish the recommended expansion dose (RDE). Part 2A is an expansion cohort using the RDE identif...